摘要
目的:探究奈达铂联合紫杉醇在晚期鼻咽癌患者中的综合应用价值。方法:选取2018年9月-2020年8月在阳江市人民医院接受化疗的80例晚期鼻咽癌患者为研究对象,随机分为对照组和观察组,每组40例。对照组采用经典的DPF治疗方案(第1天50 mg/m^(2)顺铂+75 mg/m^(2)多西他赛,第1~5天550 mg/m^(2)氟尿嘧啶),观察组采用改良TPF治疗方案(第1~5天135 mg/m^(2)紫杉醇,80 mg/m^(2)奈达铂,550 mg/m^(2)氟尿嘧啶),21 d为1个周期,连续治疗3个周期。治疗结束3个月后,对比两组近期临床治疗效果及不良反应发生情况,并应用Kaplan-Meier方法分析生存时间。结果:治疗3个月后,观察组客观缓解率(ORR)和疾病控制率(DCR)均高于对照组,但两组比较差异无统计学意义(P>0.05)。两组腹泻、恶心呕吐、肝功能损害、肾功能损害发生率比较,差异均无统计学意义(P>0.05);对照组白细胞减少、血小板减少、中性粒细胞减少及口腔黏膜炎发生率均高于观察组,差异均有统计学意义(P<0.05)。对照组中位生存时间28个月,观察组中位生存时间32个月,两组比较差异无统计学意义(P>0.05)。结论:奈达铂联合紫杉醇治疗晚期鼻咽癌与标准化疗方案有相近的近期效果和中位生存时间,且患者耐受性良好,值得临床广泛推广应用。
Objective:To explore the comprehensive application value of Nedaplatin combined with Paclitaxel in patients with advanced nasopharyngeal carcinoma.Method:A total of 80 patients with advanced nasopharyngeal carcinoma who received chemotherapy in Yangjiang People’s Hospital from September 2018 to August 2020 were selected as the research objects and randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with classic DPF regimen (on day 1,50 mg/m^(2) Cisplatin +75 mg/m^(2) Docetaxel,and on days 1-5,550 mg/m^(2) Fluorouracil),and the observation group was treated with improved TPF regimen (on days 1-5,Paclitaxel was 135 mg/m^(2),Nedaplatin 80 mg/m^(2),Fluorouracil 550 mg/m^(2)),21 days as a cycle,three consecutive cycles of treatment.After 3 months of treatment,the recent clinical treatment effects and adverse reactions of the two groups were compared,and the survival time was analyzed by Kaplan-Meier method.Result:After 3 months of treatment,the objective response rate (ORR) and disease control rate (DCR) of the observation group were higher than those of the control group,but there were no significant differences between the two groups (P>0.05).There were no significant differences in the incidences of diarrhea,nausea and vomiting,liver function damage and renal function damage between the two groups (P>0.05).The incidences of leukopenia,thrombocytopenia,neutropenia and oral mucositis in the control group were higher than those in the observation group,the differences were statistically significant (P<0.05).The median survival time of the control group was 28 months,and the median survival time of the observation group was 32 months,there was no significant difference between the two groups (P>0.05).Conclusion:Nedaplatin combined with paclitaxel in the treatment of advanced nasopharyngeal carcinoma has similar short-term efficacy and median survival time as the standard chemotherapy regimen,and the patients are well tolerated,which is worthy of wide clinical application.
作者
林琪琪
关世荣
吴盛
LIN Qiqi;GUAN Shirong;WU Sheng(Yangjiang People’s Hospital,Guangdong Province,Yangjiang 529500,China;不详)
出处
《中国医学创新》
CAS
2022年第26期143-147,共5页
Medical Innovation of China
关键词
奈达铂
紫杉醇
晚期鼻咽癌
Nedaplatin
Paclitaxel
Advanced nasopharyngeal carcinoma
作者简介
通信作者:林琪琪。
